Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

8.820 +0.030 (+0.34%)
Streaming Delayed Price Updated: 3:17 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Recursion Pharmaceuticals Inc Cl A

< Previous 1 2 Next >
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
Company to host public L(earnings) Call on May 9 at 5:00 pm ET 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
The grant designates Altitude Lab as a top acceleration program for biotechnology startups 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Host Public L(earnings) Call on February 27
From Recursion Pharmaceuticals
Via GlobeNewswire
Altitude Lab Startups Raise Over $120M in Capital
Launches Fellowship Grant Opportunity for Early Career Entrepreneurs 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Unlocking AI investment opportunities in healthcare
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Bayer and Recursion Focus Research Collaboration on Oncology
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
A growing number of companies in the biotech and healthcare industries are using AI to revolutionize drug discovery and patient care, leading to stock surges. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic... 
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.